Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Oct;205(4):1326-1336.
doi: 10.1111/bjh.19622. Epub 2024 Jul 8.

CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK

Priyanka Mehta  1 , Victoria Campbell  2 , Jamie Maddox  3 , Yngvar Floisand  4 , Anita J M Kalakonda  4   5 , Jenny O'Nions  6 , Thomas Coats  7 , Sateesh Nagumantry  8 , Katherine Hodgson  9 , Richard Whitmill  10 , Ian Amott  11 , Gillian Flynn  12 , David Taussig  13   14 , Rui Zhao  15 , Nicholas Cunningham  16 , Montse Roset  17 , Daniel Cuadras  17 , Greg Medalla  18 , Hayley Kuter  18 , Saemi Park  18 , Alex Legg  18 , Anjum B Khan  19
Affiliations
Clinical Trial

CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK

Priyanka Mehta et al. Br J Haematol. 2024 Oct.

Abstract

Favourable outcomes with CPX-351 versus conventional 7 + 3 were demonstrated in the pivotal phase III trial in adults aged 60-75 years with newly diagnosed, highrisk/secondary acute myeloid leukaemia (AML). As a complement to the clinical trial and to address important data gaps, the CPX-351 Real-World Effectiveness and SafeTy (CREST-UK; NCT05169307) study evaluated the use of CPX-351 in routine clinical practice in the UK, in 147 patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. Best response of complete remission or complete remission with incomplete platelet or neutrophil recovery was achieved by 53% of evaluable patients. Kaplan-Meier median overall survival (OS) was 12.8 months (95% confidence interval 9.2-15.3). Fifty (34%) patients proceeded to haematopoietic cell transplantation (HCT); median OS landmarked from the HCT date was not reached. There were no new safety concerns with CPX-351 identified in CREST-UK. Patients treated with CPX-351 in the outpatient setting spent an average of 24.4, 16.7, 28.2, and 27.7 fewer days on the ward compared with inpatients during first induction, second induction, first consolidation, and second consolidation, respectively. The results from CREST-UK provide valuable insights into the effectiveness, safety, and outpatient delivery of CPX-351 in routine clinical practice in the UK.

Keywords: CPX‐351; acute myeloid leukaemia; chemotherapy; clinical observations; real‐world.

PubMed Disclaimer

References

REFERENCES

    1. U.S. Food and Drug Administration. Vyxeos™ (daunorubicin and cytarabine) liposome for injection, for intravenous use. 2017.
    1. European Medicines Agency. Vyxeos liposomal 44 mg/100 mg powder for concentrate for solution for infusion. 2018.
    1. Electronic Medicines Compendium. Vyxeos liposomal summary of product characteristics. 2023.
    1. Kolitz JE, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg SL, et al. Consolidation outcomes in CPX‐351 versus cytarabine/daunorubicin‐treated older patients with high‐risk/secondary acute myeloid leukemia. Leuk Lymphoma. 2020;61(3):631–640.
    1. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX‐351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692.

Publication types

MeSH terms